On March 6, 2018 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins as a new class of potent and selective cancer medicines, reported that Drew Fromkin, President and Chief Executive Officer, will present at Cowen’s 38th Annual Health Care Conference, occurring March 12-14, 2018 in Boston, MA and Needham & Company’s 17th Annual Healthcare Conference, occurring March 27-28, 2018 in New York City (Press release, Tarveda Therapeutics, JUN 6, 2018, View Source [SID1234524525]). Tarveda presentation details:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cowen and Company 38th Annual Health Care Conference
Date: Tuesday, March 13
Time: 5:00pm Eastern Time
Location: MIT Room, Boston Marriott Copley Place, Boston, MA
Needham & Company’s 17th Annual Healthcare Conference
Date: Tuesday, March 27
Time: 1:30pm Eastern Time
Location: Westin Grand Central Hotel, New York, NY
About Pentarins
Tarveda is developing Pentarins, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell-killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell-killing payload inside the cancer cells for efficacy.